$MD
Pediatrix Medical Group, Inc. Stock $md

$md Overview Financials Valuation SEC Filings Company Website

2011 Q4 Form 10-K Financial Statement

#000119312513062738 Filed on February 15, 2013

Income Statement

Concept	2011 Q4	2011 Q3	2011 Q2
Revenue	$404.9M	$407.7M	$393.4M
YoY Change	9.88%	16.12%	12.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$287.4M	$289.7M	$278.0M
YoY Change	10.37%	16.16%	12.14%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$7.266M	$6.213M	$6.032M
YoY Change	23.15%	-1.38%	20.64%
% of Gross Profit
Operating Expenses	$313.4M	$312.6M	$300.3M
YoY Change	10.89%	15.92%	12.46%
Operating Profit	$91.51M	$95.04M	$93.12M
YoY Change
Interest Expense	$684.0K	$1.056M	$988.0K
YoY Change	-214.0%		-209.78%
% of Operating Profit	0.75%	1.11%	1.06%
Other Income/Expense, Net
YoY Change
Pretax Income	$91.33M	$94.32M	$92.46M
YoY Change	7.07%	16.01%	13.87%
Income Tax	$32.97M	$36.08M	$36.52M
% Of Pretax Income	36.1%	38.25%	39.5%
Net Earnings	$58.36M	$58.24M	$55.94M
YoY Change	8.47%	-4.99%	13.24%
Net Earnings / Revenue	14.41%	14.29%	14.22%
Basic Earnings Per Share	$1.21	$1.21	$1.18
Diluted Earnings Per Share	$1.19	$1.19	$1.15
COMMON SHARES
Basic Shares Outstanding	48.13M shares	47.99M shares	47.53M shares
Diluted Shares Outstanding	49.13M shares	48.94M shares	48.73M shares

Balance Sheet

Concept	2011 Q4	2011 Q3	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.70M	$43.00M	$34.90M
YoY Change	-47.94%	-43.12%	-5.93%
Cash & Equivalents	$18.60M	$35.75M	$23.96M
Short-Term Investments	$4.100M	$7.200M	$11.00M
Other Short-Term Assets	$7.531M	$84.00M	$76.30M
YoY Change	-89.39%	0.36%	-7.85%
Inventory
Prepaid Expenses	$6.305M
Receivables	$230.4M	$207.1M	$194.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$337.3M	$334.0M	$305.3M
YoY Change	13.94%	0.0%	2.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.53M	$61.60M	$60.10M
YoY Change	41.43%	40.0%	35.06%
Goodwill	$1.747B
YoY Change
Intangibles
YoY Change
Long-Term Investments	$45.00M	$35.00M	$25.70M
YoY Change	64.23%	18.64%	7.08%
Other Assets	$83.09M	$65.80M	$66.80M
YoY Change	18.36%	24.15%	22.57%
Total Long-Term Assets	$1.935B	$1.846B	$1.767B
YoY Change	11.13%	25.82%	20.98%
TOTAL ASSETS
Total Short-Term Assets	$337.3M	$334.0M	$305.3M
Total Long-Term Assets	$1.935B	$1.846B	$1.767B
Total Assets	$2.273B	$2.180B	$2.073B
YoY Change	11.54%	21.03%	17.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.26M	$9.800M	$10.80M
YoY Change	27.75%	19.51%	44.0%
Accrued Expenses	$222.3M	$190.2M	$148.3M
YoY Change	12.05%	-34.64%	-44.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$254.3M	$215.1M	$174.8M
YoY Change	15.02%	-30.88%	-38.75%
LONG-TERM LIABILITIES
Long-Term Debt	$29.30M	$50.40M	$66.40M
YoY Change	-80.01%	50300.0%	14.29%
Other Long-Term Liabilities	$54.54M	$163.3M	$157.7M
YoY Change	-63.27%	225.95%	206.21%
Total Long-Term Liabilities	$54.54M	$213.7M	$224.1M
YoY Change	-81.52%	325.7%	104.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$254.3M	$215.1M	$174.8M
Total Long-Term Liabilities	$54.54M	$213.7M	$224.1M
Total Liabilities	$541.6M	$517.6M	$482.5M
YoY Change	-8.23%	21.02%	5.03%
SHAREHOLDERS EQUITY
Retained Earnings	$1.006B
YoY Change
Common Stock	$489.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.731B	$1.662B	$1.590B
YoY Change
Total Liabilities & Shareholders Equity	$2.273B	$2.180B	$2.073B
YoY Change	11.54%	21.03%	17.79%

Cashflow Statement

Concept	2011 Q4	2011 Q3	2011 Q2
OPERATING ACTIVITIES
Net Income	$58.36M	$58.24M	$55.94M
YoY Change	8.47%	-4.99%	13.24%
Depreciation, Depletion And Amortization	$7.266M	$6.213M	$6.032M
YoY Change	23.15%	-1.38%	20.64%
Cash From Operating Activities	$89.80M	$100.1M	$95.30M
YoY Change	5.52%	-5.03%	3.93%
INVESTING ACTIVITIES
Capital Expenditures	-$2.700M	-$5.200M	-$3.100M
YoY Change	35.0%	79.31%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$81.80M	-$74.00M	$9.400M
YoY Change	-70.31%	413.89%	-146.53%
Cash From Investing Activities	-$84.60M	-$79.20M	$6.300M
YoY Change	-69.52%	363.16%	-126.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-22.40M	-9.100M	-92.60M
YoY Change	-114.23%	-82.83%	40.09%
NET CHANGE
Cash From Operating Activities	89.80M	100.1M	95.30M
Cash From Investing Activities	-84.60M	-79.20M	6.300M
Cash From Financing Activities	-22.40M	-9.100M	-92.60M
Net Change In Cash	-17.20M	11.80M	9.000M
YoY Change	-51.0%	-66.57%	309.09%
FREE CASH FLOW
Cash From Operating Activities	$89.80M	$100.1M	$95.30M
Capital Expenditures	-$2.700M	-$5.200M	-$3.100M
Free Cash Flow	$92.50M	$105.3M	$98.40M
YoY Change	6.2%	-2.77%	3.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5029717	shares
CY2012Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	500000000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	576030000
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50078638	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	3338146800
CY2009Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	49416000
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26503000
CY2009Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	109628000
CY2009Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	377506000
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	1190098000
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	22290000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26251000
CY2010Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	111662000
CY2010Q4	us-gaap	Sales Revenue Goods Net Percentage SalesRevenueGoodsNetPercentage	1.00	pure
CY2010Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	421977000
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	1447454000
CY2010Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20700000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7531000
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	147613000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16165000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2011Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Purchase Price BusinessAcquisitionCostOfAcquiredEntityPurchasePrice	159500000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	96600000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	254301000
CY2011Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	29443000
CY2011Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	65264000
CY2011Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	134456000
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1005881000
CY2011Q4	us-gaap	Assets Assets	2272648000
CY2011Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Cash Paid BusinessAcquisitionCostOfAcquiredEntityCashPaid	146500000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18596000
CY2011Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	234535000
CY2011Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	128000
CY2011Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	806418000
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	4139000
CY2011Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	22243000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-23517000
CY2011Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	29000000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	45.10
CY2011Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11600000
CY2011Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	109629000
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	230388000
CY2011Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	3242000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	40807000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2053573	shares
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	125721000
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	110939000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	83092000
CY2011Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	19623000
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6305000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3533000
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	93831000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2272648000
CY2011Q4	us-gaap	Cash Surrender Value Fair Value Disclosure CashSurrenderValueFairValueDisclosure	12700000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48933000	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	978353	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	489000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31300000
CY2011Q4	us-gaap	Land Land	6683000
CY2011Q4	us-gaap	Goodwill Goodwill	1746762000
CY2011Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	122847000
CY2011Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	17828000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18657000
CY2011Q4	us-gaap	Liabilities Liabilities	541632000
CY2011Q4	us-gaap	Sales Revenue Goods Net Percentage SalesRevenueGoodsNetPercentage	1.00	pure
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	470000
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	70314000
CY2011Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	79500000
CY2011Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	8700000
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	483000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	59.64
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	143000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60530000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48933000	shares
CY2011Q4	us-gaap	Long Term Investments LongTermInvestments	44991000
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	576030000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	337273000
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	724646000
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	13000000
CY2011Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	4139000
CY2011Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	13218000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13072000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2012Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.013	pure
CY2012Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Purchase Price BusinessAcquisitionCostOfAcquiredEntityPurchasePrice	451100000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	144800000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	10915000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	268338000
CY2012Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	36176000
CY2012Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	119570000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	125000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	248066000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16666000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	65191000
CY2011Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	44991000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1731016000
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	327000
CY2011Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Amount BusinessAcquisitionPurchasePriceAllocationGoodwillAmount	138600000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	54544000
CY2011Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9400000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12264000
CY2011Q4	md	Accrued Contingent Consideration AccruedContingentConsideration	-12089000
CY2011Q4	md	Accrued Professional Liability AccruedProfessionalLiability	43300000
CY2011Q4	md	Allowance For Uncollectable Accounts AllowanceForUncollectableAccounts	47459000
CY2011Q4	md	Deferred Tax Liabilities Accrual To Cash Adjustment DeferredTaxLiabilitiesAccrualToCashAdjustment	28575000
CY2011Q4	md	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	105753000
CY2011Q4	md	Equipment And Furniture EquipmentAndFurniture	96795000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	49400000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	46.46
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9228000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	160495000
CY2012Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	98503000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	6900000
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	169799000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1246788000
CY2012Q4	us-gaap	Assets Assets	2750337000
CY2012Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Cash Paid BusinessAcquisitionCostOfAcquiredEntityCashPaid	436400000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21280000
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	255661000
CY2012Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	872962000
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	6584000
CY2012Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	22957000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-56843000
CY2012Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	144000000
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	27200000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5420000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.02
CY2012Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	800000000
CY2012Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11100000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	980898	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	500000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	46300000
CY2012Q4	us-gaap	Land Land	6683000
CY2012Q4	us-gaap	Goodwill Goodwill	2165672000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	18700000
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration Potential Cash Payment BusinessAcquisitionContingentConsiderationPotentialCashPayment	0
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	624896000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	43345000
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	802000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1519644	shares
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	133789000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	112956000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Property Plant And Equipment BusinessAcquisitionPurchasePriceAllocationPropertyPlantAndEquipment	600000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4300000	shares
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	118290000
CY2012Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	12576000
CY2012Q4	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	144000000
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4852000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	108000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5624000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	21000000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	125877000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2750337000
CY2012Q4	us-gaap	Cash Surrender Value Fair Value Disclosure CashSurrenderValueFairValueDisclosure	13800000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50019000	shares
CY2012Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	137036000
CY2012Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	19787000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1474539	shares
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	12052000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18444000
CY2012Q4	us-gaap	Liabilities Liabilities	714969000
CY2012Q4	us-gaap	Sales Revenue Goods Net Percentage SalesRevenueGoodsNetPercentage	1.00	pure
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	334000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11400000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	69034000
CY2012Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	90600000
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	200000
CY2012Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	9000000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	16268000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	509000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	61.94
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59738000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	20960000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	101000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	73200000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Amortizable Intangible Assets BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssets	48200000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50019000	shares
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	12700000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	334000
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	47593000
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	624896000
CY2012Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	15900000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	359044000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	73952000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	788080000
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	14700000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	15500000
CY2012Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6584000
CY2012Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	17466000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11603000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	101000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Other Liabilities BusinessAcquisitionPurchasePriceAllocationOtherLiabilities	12000000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74051000
CY2012Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow	0
CY2012Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	47593000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	2035368000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25000000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	48800000
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	233000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Amount BusinessAcquisitionPurchasePriceAllocationGoodwillAmount	414300000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	56951000
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	14900000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	8337000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13812000
CY2012Q4	md	Accrued Contingent Consideration AccruedContingentConsideration	-16109000
CY2012Q4	md	Accrued Professional Liability AccruedProfessionalLiability	46400000
CY2012Q4	md	Allowance For Uncollectable Accounts AllowanceForUncollectableAccounts	44232000
CY2012Q4	md	Deferred Tax Liabilities Accrual To Cash Adjustment DeferredTaxLiabilitiesAccrualToCashAdjustment	33129000
CY2012Q4	md	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	136670000
CY2012Q4	md	Equipment And Furniture EquipmentAndFurniture	104149000
CY2012Q4	md	Line Of Credit Facility Potential Increase In Borrowing Capacity LineOfCreditFacilityPotentialIncreaseInBorrowingCapacity	1000000000
CY2012Q4	md	Line Of Credit Facility Reduction In Available Balance LineOfCreditFacilityReductionInAvailableBalance	5500000
CY2009Q1	md	Business Combination Contingent Consideration Arrangements Time Period BusinessCombinationContingentConsiderationArrangementsTimePeriod	P5Y
CY2010	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	684000000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.021	pure
CY2010	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	587500000
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1561000
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21950000
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-151000
CY2010	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	96570000
CY2010	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	338596000
CY2010	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3601000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-361612000
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	19035000
CY2010	us-gaap	Accretion Expense AccretionExpense	967000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	54.90
CY2010	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	3000000
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46630000	shares
CY2010	us-gaap	Investment Income Net InvestmentIncomeNet	1434000
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3486	pure
CY2010	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	1915000
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16951000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	311152000
CY2010	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	108461000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9100000
CY2010	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	26478000
CY2010	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	13910000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0035	pure
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	25693000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0010	pure
CY2010	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	16400000
CY2010	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	940000	shares
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-252000
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10330000
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	312911000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25693000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0281	pure
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.35
CY2010	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1401559000
CY2010	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	15575000
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	262000
CY2010	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	11891000
CY2010	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	24375000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	202691000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	3046000
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.26
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	9569000
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	154267000
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47570000	shares
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120802000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.35	pure
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2334000
CY2010	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1304000
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	73756000
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3882000
CY2010	us-gaap	Operating Expenses OperatingExpenses	1088648000
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	948000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.023	pure
CY2010	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	1700000
CY2010	us-gaap	Interest Paid Net InterestPaidNet	2559000
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	108461000
CY2010	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	13357000
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-38918000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	14400000
CY2010	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	18200000
CY2010	us-gaap	Labor And Related Expense LaborAndRelatedExpense	854920000
CY2010	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-2781356000
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	3043000
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	500000
CY2010	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8500000
CY2010	us-gaap	Depreciation Depreciation	13500000
CY2010	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	88601000
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25700000
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	464000	shares
CY2010	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	19800000
CY2010	us-gaap	Interest Expense InterestExpense	3193000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.89
CY2010	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	18706000
CY2010	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	553000
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	22532000
CY2010	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	2825827000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	22814000
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	240558000
CY2010	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	12113000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0242	pure
CY2010	md	Excess Tax Benefit Related To Resolution Of Income Tax Matters ExcessTaxBenefitRelatedToResolutionOfIncomeTaxMatters	3394000
CY2010	md	Health Care Organization Patient Service Revenue Gross HealthCareOrganizationPatientServiceRevenueGross	4140312000
CY2010	md	Payments Of Contingent Consideration Liabilities PaymentsOfContingentConsiderationLiabilities	4405000
CY2010	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	57511000
CY2010	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	-27086000
CY2010	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	11142000
CY2010	md	Reduction In Its Income Tax Provision Resulting From Resolution Of Tax Matters ReductionInItsIncomeTaxProvisionResultingFromResolutionOfTaxMatters	10900000
CY2010	md	Stock Issued During Period Value Stock Options Exercised And Stock Purchase Plans StockIssuedDuringPeriodValueStockOptionsExercisedAndStockPurchasePlans	22532000
CY2010	md	Total Provision For Losses TotalProvisionForLosses	-15944000
CY2010	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	2825827000
CY2010	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	-87074000
CY2011	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	512500000
CY2011	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	630000000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	577000
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25292000
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1959000
CY2011	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	120776000
CY2011	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	154885000
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3932000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190573000
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	7203000
CY2011	us-gaap	Accretion Expense AccretionExpense	1083000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	70.99
CY2011	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	7100000
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47706000	shares
CY2011	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	5.35
CY2011	us-gaap	Investment Income Net InvestmentIncomeNet	1495000
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3829	pure
CY2011	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	9843000
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48993000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	353245000
CY2011	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	135248000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14100000
CY2011	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	42526000
CY2011	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	11747000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0032	pure
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	27092000
CY2011	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1950972000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0013	pure
CY2011	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	24500000
CY2011	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1090000	shares
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7655000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13895000
CY2011	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	255183000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	355389000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27092000
CY2011	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	48796000	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0044	pure
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.57
CY2011	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1588248000
CY2011	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	38170000
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	463000
CY2011	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	14472000
CY2011	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8063000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	217997000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2011	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	7111000
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.47
CY2011	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	47706000	shares
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-88101000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.35	pure
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	170356000
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48796000	shares
CY2011	md	Line Of Credit Facility Payments For Amendment LineOfCreditFacilityPaymentsForAmendment	1970000
CY2011	md	Number Of Physician Group Practices NumberOfPhysicianGroupPractices	10	Company
CY2011	md	Payments Of Contingent Consideration Liabilities PaymentsOfContingentConsiderationLiabilities	6561000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2541000
CY2011	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1520000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	113290000
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3433000
CY2011	us-gaap	Operating Expenses OperatingExpenses	1232859000
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	44000
CY2011	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	400000
CY2011	us-gaap	Interest Paid Net InterestPaidNet	2569000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	135248000
CY2011	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	11526000
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	21480000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	19000000
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	20300000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.3829	pure
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	7031000
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	-13000
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10300000
CY2011	us-gaap	Depreciation Depreciation	15000000
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	119261000
CY2011	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	32400000
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27100000
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45000	shares
CY2011	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	20800000
CY2011	us-gaap	Labor And Related Expense LaborAndRelatedExpense	970396000
CY2011	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	751000
CY2011	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	145400000
CY2011	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-3208028000
CY2011	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	5.23
CY2011	us-gaap	Interest Expense InterestExpense	3639000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.27
CY2011	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6704000
CY2011	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	221000
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31362000
CY2011	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	3362081000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7486000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	271019000
CY2011	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	31332000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0266	pure
CY2011	md	Decrease In Uncertain Tax Position DecreaseInUncertainTaxPosition	6100000
CY2011	md	Health Care Organization Patient Service Revenue Gross HealthCareOrganizationPatientServiceRevenueGross	4851500000
CY2011	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	66815000
CY2011	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	-33031000
CY2011	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	10099000
CY2011	md	Stock Issued During Period Value Stock Options Exercised And Stock Purchase Plans StockIssuedDuringPeriodValueStockOptionsExercisedAndStockPurchasePlans	31362000
CY2011	md	Total Provision For Losses TotalProvisionForLosses	-22932000
CY2011	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	3362081000
CY2011	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	-98829000
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000893949
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Trading Symbol TradingSymbol	MD
CY2012	dei	Entity Registrant Name EntityRegistrantName	MEDNAX, INC.
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2012	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	517500000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P10M24D
CY2012	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	402500000
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	528135	shares
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1530000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30816000
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	411000
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	131754000
CY2012	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	441006000
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1153000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-460548000
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	3671000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	39.33
CY2012	us-gaap	Accretion Expense AccretionExpense	995000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	60.11
CY2012	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	6200000
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48693000	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2012	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	5.35
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	1896000
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3794	pure
CY2012	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	9941000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	54.30
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17678000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	388171000
CY2012	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	147264000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	18100000
CY2012	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	33120000
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	13133000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0036	pure
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	28437000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2012	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2015167000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0013	pure
CY2012	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	20800000
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	998000	shares
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2684000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13980000
CY2012	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	260485000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	389520000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28437000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	68.56
CY2012	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	49691000	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0015	pure
CY2012	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	650500000
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.95
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.     General:</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The principal business activity of MEDNAX, Inc. (“MEDNAX” or the “Company”) and its subsidiaries is to provide neonatal, maternal-fetal, other pediatric subspecialties and anesthesia physician services. The Company has contracts with affiliated professional associations, corporations and partnerships (“affiliated professional contractors”), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include (i) fee-for-service contracts, whereby hospitals agree, in exchange for the Company’s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company’s affiliated healthcare professionals, and (ii) administrative fee contracts, whereby the Company is assured a minimum revenue level.</font></p> </div>
CY2012	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1816612000
CY2012	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2017-11-17
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2012	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	28073000
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	136000
CY2012	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	15510000
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	21344000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	240907000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2012	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	6198000
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.85
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	12900000
CY2012	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	48693000	shares
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	193540000
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49691000	shares
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137540000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	12564000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	465317	shares
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16953000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2478000
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2002000
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	111940000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	423331	shares
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	244000
CY2012	us-gaap	Operating Expenses OperatingExpenses	1427092000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	102000
CY2012	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	300000
CY2012	us-gaap	Interest Paid Net InterestPaidNet	2044000
CY2012	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P1Y10M24D
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	147264000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	39441	shares
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	24800000
CY2012	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1130913000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	23000000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	6494000
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15000000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5794	shares
CY2012	us-gaap	Depreciation Depreciation	15800000
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	129636000
CY2012	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	37700000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28400000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29000	shares
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	23900000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Accounting Estimates and Assumptions</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company’s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company’s professional liability risks, the fair value of goodwill, and liabilities for uncertain tax positions. Actual results could differ from those estimates.</font></p> </div>
CY2012	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	418900000
CY2012	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-3946058000
CY2012	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-7343000
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	569000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28810000
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	3994924000
CY2012	md	Number Of Physician Group Practices NumberOfPhysicianGroupPractices	16	Company
CY2012	md	Long Term Investment Maturity Maximum LongTermInvestmentMaturityMaximum	6	Y
CY2012	md	Long Term Investment Maturity Minimum LongTermInvestmentMaturityMinimum	1	Y
CY2012	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	5.24
CY2012	us-gaap	Interest Expense InterestExpense	3245000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	19814000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	325692000
CY2012	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	14495000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0260	pure
CY2012	md	Assumed Payment Probability Of Contingent Consideration Payment AssumedPaymentProbabilityOfContingentConsiderationPayment	1.00	pure
CY2012	md	Contingent Consideration Payments Related To Prior Period Acquisitions ContingentConsiderationPaymentsRelatedToPriorPeriodAcquisitions	14700000
CY2012	md	Decrease In Uncertain Tax Position DecreaseInUncertainTaxPosition	3100000
CY2012	md	Health Care Organization Patient Service Revenue Gross HealthCareOrganizationPatientServiceRevenueGross	5691790000
CY2012	md	Increase In Uncertain Tax Position IncreaseInUncertainTaxPosition	1100000
CY2012	md	Line Of Credit Facility Payments For Amendment LineOfCreditFacilityPaymentsForAmendment	2397000
CY2012	md	Payments Of Contingent Consideration Liabilities PaymentsOfContingentConsiderationLiabilities	10231000
CY2012	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	71823000
CY2012	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	-35441000
CY2012	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	8119000
CY2011Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	75134000
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	75720000
CY2011Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.96
CY2011Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	382283000
CY2011Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48730000	shares
CY2012	md	Schedule Of Differences Between Federal Statutory Tax Rate And Effective Tax Rate ScheduleOfDifferencesBetweenFederalStatutoryTaxRateAndEffectiveTaxRate	<div> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The differences between the effective rate and the United States federal income tax statutory rate are as follows:</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">  </p> <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="75%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2010</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Tax at statutory rate</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">35.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">35.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">35.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">State income tax, net of federal benefit</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2.60</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2.66</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2.42</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Non-deductible expenses</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0.36</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0.32</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Change in accrual estimates relating to uncertain tax positions</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(0.15</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0.44</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(2.81</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other, net</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0.13</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(0.13</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(0.10</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Income tax provision</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">37.94</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">38.29</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">34.86</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> </tr> </table> </div>
CY2012	md	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAveragePeriod	1.4	Y
CY2012	md	Stock Issued During Period Value Stock Options Exercised And Stock Purchase Plans StockIssuedDuringPeriodValueStockOptionsExercisedAndStockPurchasePlans	28810000
CY2012	md	Time Period For Achievement Of Certain Performance Measures For Payment Of Contingent Consideration TimePeriodForAchievementOfCertainPerformanceMeasuresForPaymentOfContingentConsideration	5	Y
CY2012	md	Time Taken For Contingent Purchase Price Provisions Payments Due TimeTakenForContingentPurchasePriceProvisionsPaymentsDue	2017
CY2012	md	Total Provision For Losses TotalProvisionForLosses	-27322000
CY2012	md	Additional Contingent Consideration For Business Acquisition AdditionalContingentConsiderationForBusinessAcquisition	5000000
CY2012	md	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Weighted Average Grant Date Fair Value One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageGrantDateFairValueOne	65.06
CY2012	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	3994924000
CY2012	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	-119746000
CY2011Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5781000
CY2011Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47149000	shares
CY2011Q1	us-gaap	Investment Income Net InvestmentIncomeNet	325000
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	45456000
CY2011Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.94
CY2011Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41798000
CY2011Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48361000	shares
CY2011Q1	us-gaap	Operating Expenses OperatingExpenses	306563000
CY2011Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29678000
CY2011Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	243894000
CY2011Q1	us-gaap	Interest Expense InterestExpense	911000
CY2011Q1	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	15090000
CY2011Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6032000
CY2011Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47531000	shares
CY2011Q2	us-gaap	Investment Income Net InvestmentIncomeNet	329000
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	92464000
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	93123000
CY2011Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.18
CY2011Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	393402000
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	55941000
CY2011Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.15
CY2011Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42702000
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	300279000
CY2011Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36523000
CY2011Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	235292000
CY2011Q2	us-gaap	Interest Expense InterestExpense	988000
CY2011Q2	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	16253000
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7113000
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48269000	shares
CY2012Q1	us-gaap	Investment Income Net InvestmentIncomeNet	428000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	79262000
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	79388000
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2012Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	422616000
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	48350000
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46869000
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49399000	shares
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	343228000
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30912000
CY2012Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	272261000
CY2012Q1	us-gaap	Interest Expense InterestExpense	554000
CY2012Q1	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	16985000
CY2012Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7687000
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48543000	shares
CY2012Q2	us-gaap	Investment Income Net InvestmentIncomeNet	365000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	99253000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	99736000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.25
CY2012Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	449530000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	60544000
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.22
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48200000
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49545000	shares
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	349794000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38709000
CY2012Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	275951000
CY2012Q2	us-gaap	Interest Expense InterestExpense	848000
CY2012Q2	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	17956000
CY2011Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6213000
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47990000	shares
CY2011Q3	us-gaap	Investment Income Net InvestmentIncomeNet	337000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	94318000
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	95037000
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.21
CY2011Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	407665000
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	58241000
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.19
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43010000
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48935000	shares
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	312628000
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36077000
CY2011Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	246687000
CY2011Q3	us-gaap	Interest Expense InterestExpense	1056000
CY2011Q3	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	16718000
CY2012Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7925000
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48938000	shares
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	422000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	107171000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	107373000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.35
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	473134000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	65910000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48200000
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49809000	shares
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	365761000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41261000
CY2012Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	292030000
CY2012Q3	us-gaap	Interest Expense InterestExpense	624000
CY2012Q3	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	17606000
CY2011Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7266000
CY2011Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48126000	shares
CY2011Q4	us-gaap	Investment Income Net InvestmentIncomeNet	504000
CY2011Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	91329000
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	91509000
CY2011Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.21
CY2011Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	404898000
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	58359000
CY2011Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.19
CY2011Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42846000
CY2011Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49132000	shares
CY2011Q4	us-gaap	Operating Expenses OperatingExpenses	313389000
CY2011Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32970000
CY2011Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	244523000
CY2011Q4	us-gaap	Interest Expense InterestExpense	684000
CY2011Q4	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	18754000
CY2012Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8091000
CY2012Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49113000	shares
CY2012Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50106000	shares
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	368309000
CY2012Q4	us-gaap	Investment Income Net InvestmentIncomeNet	681000
CY2012Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	102485000
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	103023000
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.35
CY2012Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	471332000
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	66103000
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50271000
CY2012Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36382000
CY2012Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	290671000
CY2012Q4	us-gaap	Interest Expense InterestExpense	1219000
CY2012Q4	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	19276000

Files In Submission

Name	View Source	Status
0001193125-13-062738-index-headers.html	Edgar Link	pending
0001193125-13-062738-index.html	Edgar Link	pending
0001193125-13-062738.txt	Edgar Link	pending
0001193125-13-062738-xbrl.zip	Edgar Link	pending
d456148d10k.htm	Edgar Link	pending
d456148dex1024.htm	Edgar Link	pending
d456148dex211.htm	Edgar Link	pending
d456148dex231.htm	Edgar Link	pending
d456148dex311.htm	Edgar Link	pending
d456148dex312.htm	Edgar Link	pending
d456148dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g456148g48w32.jpg	Edgar Link	pending
md-20121231.xml	Edgar Link	completed
md-20121231.xsd	Edgar Link	pending
md-20121231_cal.xml	Edgar Link	unprocessable
md-20121231_def.xml	Edgar Link	unprocessable
md-20121231_lab.xml	Edgar Link	unprocessable
md-20121231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MD
Pediatrix Medical Group, Inc. Stock $md

2011 Q4 Form 10-K Financial Statement

#000119312513062738 Filed on February 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD Pediatrix Medical Group, Inc. Stock $md

2011 Q4 Form 10-K Financial Statement

#000119312513062738 Filed on February 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD
Pediatrix Medical Group, Inc. Stock $md